Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2025 | Evaluating predictors of benefit of CDK4/6 inhibition in breast cancer

Fabrice André • 14 May 2025
ESMO Breast 2025
Breast Cancer Abemaciclib Palbociclib

Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses whether specific patient or molecular profiles influence outcomes from continued CDK4/6 inhibition following disease progression in HR-positive, HER2-negative breast cancer. Observed outcomes are more closely tied to the choice and sequence of CDK4/6 inhibitors—particularly when switching from palbociclib to abemaciclib—rather than the identification of genomic alterations or patient subgroups. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fabrice André

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer
1:17
KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer
Fabrice André • 14 May 2025
DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer
1:18
DESTINY-Breast07: updated results of first line T-DXd in HER2+ breast cancer
Fabrice André • 14 May 2025
Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy?
1:32
Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy?
Fabrice André • 14 May 2025
CANTO: improving the quality of life of women treated for localized breast cancer
2:17
CANTO: improving the quality of life of women treated for localized breast cancer
Fabrice André • 11 Sep 2022

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals